Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2023 | Temporal arteritis: treatment duration and disease monitoring

Bruno Gran, MD, PhD, FRCP, The University of Nottingham, Nottingham, UK, discusses unanswered questions in the treatment of temporal arteritis. The optimal duration of treatment, not only of tocilizumab but also of corticosteroids, remains undetermined. Additionally, inflammatory activity is not easy to monitor. In clinical practice, the most widely used biomarkers are the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). However, these indices may be within normal limits during disease relapse, and they are not reliable in patients receiving drugs that suppress acute-phase proteins. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Gran has received personal compensation for consultancy from Merck, Roche, Biogen, Teva UK, and GW Pharma

Dr Gran has received unrestricted research grants from Biogen Idec, Merck, Bayer Healthcare, Teva UK, Novartis, and Genzyme

Dr Gran has received support for the attendance of clinical and research conferences from Biogen, Merck, Bayer Healthcare, Teva UK, Novartis, Genzyme, and CelGene